<ruby id="9ue20"></ruby>

  1. 
    

      国产午夜福利免费入口,国产日韩综合av在线,精品久久人人妻人人做精品,蜜臀av一区二区三区精品,亚洲欧美中文日韩在线v日本,人妻av中文字幕无码专区 ,亚洲精品国产av一区二区,久久精品国产清自在天天线
      網易首頁 > 網易號 > 正文 申請入駐

      “以光為刃”,當傳統工藝無解,藥明康德如何將新藥化學合成的鴻溝化為坦途?

      0
      分享至

      在新藥研發道路上,有時候決定成敗的往往不是宏大的敘事,而是一次關鍵化學中間體的高效合成。這類中間體如同精密的齒輪,其結構的細微偏差,都可能導致后續進程的停滯。在藥明康德的眾多客戶里,許多重要合作常常始于一個看似微小卻至關重要的化學工藝節點。

      故事要從一個棘手的分子骨架說起。

      某公司在推進一個極具潛力的分子項目時,被一個關鍵的“路障”卡住了。項目急需構建一個復雜而精確的三維分子骨架。這個骨架,是整個藥物分子的“心臟”,它的形狀、空間結構都必須分毫不差。因此,只有成功構建出正確立體構型的核心骨架,才能構建出具有生物活性的復雜分子,進而有望推進臨床,拯救生命。

      然而,擺在他們面前的,是行業內傳統分批工藝的“瓶頸”。

      傳統分批工藝生產模式是將所有原料按順序投入反應容器中,在設定好的溫度、壓力下攪拌、反應。待反應結束,再進行分離提純,得到產物。在這個項目中,如果采用傳統合成路線,需經過5步反應,效率較低。而且,最終得到的產物里,只有一半是符合要求的立體構型,整體收率也不高。

      更為棘手的是,傳統分批工藝從實驗室的克級探索放大到千克級生產時,橫亙著一條難以逾越的“鴻溝”。這不是簡單地把原料配方乘以1000就能解決的。規模放大后,反應體系的物理環境會發生變化,許多在燒瓶中運行良好的反應,一旦進入大釜,就可能面臨效率下降、甚至失敗風險。要解決這些挑戰,就需要耗費更多時間和資源來重新摸索工藝條件。

      面對難題,該公司第一時間聯系上藥明康德研發化學服務部(Research Chemistry Services,RCS)。這種信任并非憑空而來。它是十多年間,在多個合作項目里,由藥明康德一次次專業、高效的服務交付,一點一滴積累起來的。

      接到任務后,藥明康德RCS團隊迅速組建了由多個研發和生產基地專家構成的項目團隊,一場與時間賽跑的技術攻堅就此拉開序幕。

      如何破解分批工藝收率低、順反選擇性差,以及難以放大的“死結”?團隊的目光投向了光化學工藝技術。


      所謂光化學工藝,是利用特定波長的光能作為“精確的刻刀”,代替傳統的熱能或化學試劑,來精準切斷或重組化學鍵,從而高效構建目標分子。這聽起來似乎有些深奧,但光化學離我們的生活并不遙遠,就像晾在陽臺的彩色衣物,時間久了會慢慢褪色,其實是染料分子在太陽光的照射下發生了光化學反應;或是老式膠片相機按下快門的瞬間,膠片上的感光材料會因吸收光線而發生化學變化,最終定格下影像,也是光化學的典型應用。然而,當光化學技術應用于工業場景時,對設備、對人員的專業素養要求極高,它需要光能均勻、穩定地穿透反應體系,這在傳統的反應釜中幾乎無法實現。

      為此,項目團隊引入了一套高效的技術“組合拳”。

      首先登場的是高通量實驗(HTE),如果說分批工藝是在黑暗中一把把地嘗試“鑰匙”,那HTE就像同時啟動了上百個微型“智能鑰匙”,它能在極短時間內并行測試數百種反應條件——換一種光波長、試一種新催化劑、調一下濃度——過去需要幾周甚至幾個月的摸索,現在可將項目初期的摸索時間壓縮到以天計,從而迅速鎖定關鍵“配方”。

      但僅找到“配方”還不夠,關鍵是如何讓它穩定、高效地運轉起來,并適用于規模放大。于是,流動化學技術便登場亮相。

      想象一下,不再讓原料悶在反應容器里“不均勻光照”,而是將它們像輸液一樣,通過細細的管道持續泵入一個盤成線圈的透明“光隧道”。反應物一邊勻速流動,一邊接受管道外壁均勻的光照,真正實現了“邊走邊反應”。

      在這條精心設計的“光隧道”上,光照條件均勻穩定,反應路徑精準可控。原本需要5步、多批次投放、多次分離、轉移的復雜過程,如今像一條流水線,僅需1步連貫完成。

      結果是令人驚喜的——產物收率良好,順式選擇性極高。更難得的是,項目團隊僅用了9個小時,就完成了100克以上規模的精準制備,這意味著該工藝路線已成功跨越實驗室研究階段,具備了直接為后續毒理研究、臨床試驗提供足量藥物的能力,也為未來更大規模化生產奠定了堅實的技術基礎。這種效率與質量的雙重提升,使得原本預估需要4個多月的項目工期,被大幅縮短至僅10周。

      當項目團隊將高質量的產物交付到客戶手中時,客戶的項目負責人難掩興奮,高度贊賞道:“你們對光化學工藝的掌握和應用令人印象深刻,新的技術為我們打開了路線優化的大門,不僅提高了產量,也讓規模放大成為可能。”

      如今,這家客戶仍有多個后續項目與藥明康德持續合作。


      圖片來源:123RF

      這不僅是藥明康德光化學平臺一次高質量的服務交付,更是公司“讓天下沒有難做的藥,難治的病”這一愿景在微觀層面的生動注腳。這一成功的賦能案例,不僅彰顯了藥明康德在光化學領域的技術深度,更是公司全面化學能力的堅實印證,是公司CRDMO全球賦能平臺在創新浪潮中的一個典型縮影。

      回首二十余載,藥明康德構建的一體化、端到端CRDMO賦能平臺,早已超越了單純的技術疊加。公司將光化學、電化學、流動化學、酶催化等一系列創新技術融會貫通,以更好地賦能全球合作伙伴。因為,每一次分子的合成,背后都是滿懷期待的科學家和客戶,以及等待救治的患者。正是這份敬畏與擔當,驅動公司支持全球數千家合作伙伴破解研發挑戰,加速新藥從分子走向臨床的過程,讓創新療法突破瓶頸,推動更多新藥、好藥早日問世。

      Light and Flow: How WuXi AppTec Bridges the Gap in Novel Drug Chemical Synthesis

      In the journey of new drug development, success or failure often hinges on the efficient synthesis of a single, critical chemical intermediate—far more than on grand narratives. Among WuXi AppTec’s many customers, numerous significant collaborations begin at what may seem like a minor but is in fact a pivotal point in the chemical process.

      The story starts with a challenging molecular scaffold.

      A company was advancing a highly promising molecule when it hit a critical roadblock. The project urgently required the construction of a complex and precise three-dimensional molecular scaffold. This scaffold was the “heart” of the drug molecule; its shape and spatial structure had to be flawless. Therefore, successfully constructing this core scaffold with correct stereo configuration was the only way to build a biologically active complex molecule, ultimately advancing it toward clinical trials and the potential to save lives.

      However, the team faced a bottleneck inherent to traditional batch processing.

      In traditional batch processing, all raw materials are sequentially added to a reaction vessel, stirred, and reacted under set temperature and pressure conditions. Once the reaction is complete, the product is isolated and purified.For this project, the conventional synthetic route would have required five reaction steps, resulting in low efficiency. Moreover, only about half of the final product possessed the required stereo configuration, and the overall yield was low.

      An even greater challenge was the significant gap between gram-scale laboratory exploration and kilogram-scale production using traditional batch methods. This scaling-up process is not a simple matter of multiplying the recipe by a factor of 1000. When a process is scaled up, the physical environment of the reaction system changes. Many reactions that work smoothly in a flask may face decreased efficiency or even fail when transferred to a large reactor. Overcoming these challenges would require substantial additional time and resources to re-optimize the process conditions.

      Faced with this challenge, the company immediately contacted WuXi AppTec’s Research Chemistry Services (RCS) team. This trust was not built overnight. It has been accumulated over more than a decade through multiple collaborative projects, earned through consistent delivery of professional and efficient services.

      Upon receiving the task, the RCS team quickly pulled together experts from multiple sites—kicking off a race against time to tackle the technical challenge.

      How could they solve the intertwined problems of low yield, poor cis-trans selectivity, and the difficulty of scaling up the batch process? The team’s focus turned to photochemistry.


      Photochemistry uses light energy of a specific wavelength as a “precision chisel,” replacing traditional thermal energy or chemical reagents to precisely break or reform chemical bonds, efficiently constructing the target molecule.While this might sound complex, photochemistry is not far from our daily lives. For example, colored clothes left to dry on a balcony slowly fade over time because the dye molecules undergo photochemical reactions under sunlight. Similarly, when a vintage film camera shutter clicks, the photosensitive material on the film absorbs light and undergoes a chemical change, capturing the image—a classic application of photochemistry. However, applying photochemistry in an industrial setting demands highly specialized equipment and expertise. It requires the light energy to penetrate the reaction system uniformly and stably, a feat nearly impossible in traditional reaction vessels.

      To address this, the project team implemented a powerful combination of technologies.

      The first was High-Throughput Experimentation (HTE). If batch processing is like trying keys one by one in the dark, HTE is like activating hundreds of miniature “smart keys” simultaneously. It allows hundreds of reaction conditions—varying the light wavelength, trying a new catalyst, adjusting the concentration—to be tested in parallel within a very short time. What used to take weeks or even months of exploration could now be compressed into days, enabling the team to rapidly lock in a critical “formula.”

      But finding the formula was only half the battle. The key was to make it run stably, efficiently, and in a scalable manner. This is where flow chemistry came into play.

      Imagine, instead of having the raw materials confined in a reactor with uneven light exposure, they were continuously pumped like an intravenous drip through a narrow tube coiled into a transparent “light tunnel.” As the reactants flowed at a constant rate, they received uniform illumination from the outside of the tube wall, truly achieving “reaction on the go.”

      Within this precisely engineered “light tunnel,” the light exposure was consistent and stable, and the reaction pathway was precisely controlled.The original complex process requiring five steps, multiple batch additions, and multiple separations and transfers was streamlined like an assembly line, completed in continuous flow in one step.

      The results were remarkable: excellent product yield, exceptionally high cis-selectivity, andprecise preparation of over 100 grams in just nine hours. This demonstrated that the process had successfully crossed the laboratory research stage, enabling the possibility to directly supply sufficient quantity of the drug candidate for subsequent toxicology studies and clinical trials, and laying a solid technical foundation for future large-scale production.This dual improvement in efficiency and quality shortened the project timeline significantly, from an estimated over four months to just ten weeks.

      When the project team delivered the high-quality product to the client, the client’s project lead couldn’t hide their excitement. "The photochemical process had opened the door to route optimization for us, not only increasing yield but also making it possible to scale-up."

      Since then, this client has continued to collaborate with WuXi AppTec on multiple subsequent projects.


      Image source: 123RF

      This case represents more than just a high-quality service delivery by WuXi AppTec’s photochemistry platform; it is a tangible microcosm of the company’s vision: “Every drug can be made, and every disease can be treated.” This successful enabling story not only highlights WuXi AppTec’s technical depth in the field of photochemistry but also stands as a solid testament to its comprehensive chemistry capabilities, serving as a quintessential example of its global CRDMO enabling platform in action amidst a wave of innovation.

      Looking back over more than two decades, WuXi AppTec’s integrated, end-to-end CRDMO enabling platform has gone beyond a mere collection of technologies. The company has integrated and mastered a suite of innovative technologies—including photochemistry, electrochemistry, flow chemistry, enzymatic catalysis, and beyond—to better enable its global partners. Behind every synthesis of a molecule, what we see are scientists and clients full of anticipation, as well as patients waiting for treatment. It is this sense of respect and responsibility that drives the company to support thousands of customers worldwide in tackling R&D challenges, accelerating the journey of new drugs from molecule to clinical, breaking through bottlenecks in innovative therapies, and helping bring more new and better medicines to patients faster.

      免責聲明:本文僅作信息交流之目的,文中觀點不代表藥明康德立場,亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導,請前往正規醫院就診。

      版權說明:歡迎個人轉發至朋友圈,謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”,獲取轉載須知。

      特別聲明:以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布,本平臺僅提供信息存儲服務。

      Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.

      相關推薦
      熱點推薦
      局勢走向失控?中俄朝強勢按住日本,東京傳來消息,高市被催辭職

      局勢走向失控?中俄朝強勢按住日本,東京傳來消息,高市被催辭職

      軒逸阿II
      2026-05-17 01:14:06
      難怪以色列要暴打伊朗,原來伊朗人才是“真”雅利安人

      難怪以色列要暴打伊朗,原來伊朗人才是“真”雅利安人

      南宗歷史
      2026-05-17 20:59:19
      蔚來總裁秦力洪:大部分超豪華車就不該賣100萬以上,在歐洲賣5萬歐元為什么到中國就賣100多萬?

      蔚來總裁秦力洪:大部分超豪華車就不該賣100萬以上,在歐洲賣5萬歐元為什么到中國就賣100多萬?

      新浪財經
      2026-05-16 20:52:15
      上海VS北京G2,許利民透露核心復出,盧偉表態務實,裁判安排出爐

      上海VS北京G2,許利民透露核心復出,盧偉表態務實,裁判安排出爐

      萌蘭聊個球
      2026-05-17 14:31:22
      就在今日!西決馬刺VS雷霆首個大問題浮現,文班亞馬為湖人出頭

      就在今日!西決馬刺VS雷霆首個大問題浮現,文班亞馬為湖人出頭

      等等talk
      2026-05-17 15:59:28
      尤文0-2佛羅倫薩跌至第六:1億歐損失當頭,四重困局誰能破解?

      尤文0-2佛羅倫薩跌至第六:1億歐損失當頭,四重困局誰能破解?

      落夜足球
      2026-05-17 21:10:28
      9架運-20B同框亮相,跟美國的C-17相比,中國的運20很落后嗎?

      9架運-20B同框亮相,跟美國的C-17相比,中國的運20很落后嗎?

      夢史
      2026-05-17 03:23:14
      俄羅斯令中國失望?最可怕的不是西方的封鎖,而是我們輕視了自己

      俄羅斯令中國失望?最可怕的不是西方的封鎖,而是我們輕視了自己

      時尚的弄潮
      2026-05-16 16:22:50
      張雪機車后吉利星瑞TCR奪冠,中國制造刷新世界認知

      張雪機車后吉利星瑞TCR奪冠,中國制造刷新世界認知

      華夏時報
      2026-05-17 08:30:03
      歷史不會重演,但會驚人相似:中國房地產很有可能重走日本老路?

      歷史不會重演,但會驚人相似:中國房地產很有可能重走日本老路?

      笑熬漿糊111
      2026-05-11 05:00:12
      16-14!歐冠決賽:樊振東莫雷加德戰勒布倫兄弟

      16-14!歐冠決賽:樊振東莫雷加德戰勒布倫兄弟

      吳锎旅行ing
      2026-05-17 05:06:01
      中國做出兩個承諾!特朗普親口證實:不提供軍武、幫忙通海峽

      中國做出兩個承諾!特朗普親口證實:不提供軍武、幫忙通海峽

      Ck的蜜糖
      2026-05-17 21:28:05
      黃瓜立大功?醫生發現:經常吃黃瓜的人,不出半年,或有4大改善

      黃瓜立大功?醫生發現:經常吃黃瓜的人,不出半年,或有4大改善

      芹姐說生活
      2026-05-09 21:08:03
      北京這一天,劉詩詩憔悴脫相,吉克雋逸黑又壯,張柏芝臉咋僵成這

      北京這一天,劉詩詩憔悴脫相,吉克雋逸黑又壯,張柏芝臉咋僵成這

      阿郎娛樂
      2026-05-15 17:09:19
      世界超級摩托車錦標賽“張雪機車”拿下第五冠

      世界超級摩托車錦標賽“張雪機車”拿下第五冠

      環球網資訊
      2026-05-17 20:50:07
      麻生太郎也坐不住了,沒想到中國還要回訪美國!

      麻生太郎也坐不住了,沒想到中國還要回訪美國!

      阿龍聊軍事
      2026-05-16 14:32:29
      女子因18元奶茶被親姐拉黑,崩潰大哭:離婚帶娃5年,都看不起我

      女子因18元奶茶被親姐拉黑,崩潰大哭:離婚帶娃5年,都看不起我

      辣媒專欄記錄
      2026-05-11 08:21:59
      俄羅斯威脅亞美尼亞,如果退出歐亞經濟聯盟,將面臨嚴重后果

      俄羅斯威脅亞美尼亞,如果退出歐亞經濟聯盟,將面臨嚴重后果

      山河路口
      2026-05-16 20:55:13
      東風導彈泄密案!間諜郭萬鈞一家三口,全部被處以死刑

      東風導彈泄密案!間諜郭萬鈞一家三口,全部被處以死刑

      番外行
      2026-03-31 08:28:28
      已成功瘦了10斤,我發現提高代謝最掉秤的是:早餐吃2個雞蛋!

      已成功瘦了10斤,我發現提高代謝最掉秤的是:早餐吃2個雞蛋!

      牛鍋巴小釩
      2026-05-17 20:40:55
      2026-05-17 21:56:49
      藥明康德 incentive-icons
      藥明康德
      創建賦能平臺,承載醫藥夢想
      8307文章數 17543關注度
      往期回顧 全部

      科技要聞

      三大運營商即將免月租?多方回應

      頭條要聞

      相隔不到一周 北京又將迎來一位大國元首

      頭條要聞

      相隔不到一周 北京又將迎來一位大國元首

      體育要聞

      生死戰只拿3分的核心,還有留的必要嗎?

      娛樂要聞

      盧昱曉道歉:認識到問題嚴重性!

      財經要聞

      長鑫科技 預計上半年凈利至少500億元

      汽車要聞

      車長超5米/雙動力可選 昊鉑S600預售權益價18.89萬起

      態度原創

      時尚
      健康
      本地
      旅游
      軍事航空

      “這條裙子”是今年夏天的頂流!誰穿誰好看

      專家揭秘干細胞回輸的安全風險

      本地新聞

      用蘇繡的方式,打開江西婺源

      旅游要聞

      桑果飄香?綠道摘鮮繪鄉韻 北京旅游休閑綠道資源推介暨第25屆安定古桑文化主題月活動啟幕

      軍事要聞

      黎以停火再延長 空襲卻未停止

      無障礙瀏覽 進入關懷版 主站蜘蛛池模板: 丁香亚洲综合五月天婷婷| 国产精品自在自线视频| 欧美精品一区二区三区中文字幕 | 人妻制服OL熟女の美脚| 国产精品深夜福利免费观看| 中文字幕人妻视频| 国产精品视频亚洲二区| 亚洲AV在线观看| 男人的天堂av一二三区| 亚洲日韩av无码中文字幕美国| 又爽又黄又粗又大免费视频| 无码国产偷倩在线播放| 9191久久| 国产精品国产三级国产专i| 久久青草精品38国产免费| 国产成人高清精品亚洲| 亚洲精品国品乱码久久久久| 久久躁日日躁AAAAXXXX| 男人天堂2018亚洲男人天堂| 亚洲成av人片无码迅雷下载| 国内极度色诱视频网站| 国产精品久久久久久福利69堂| 亚洲一二三四五区视频| 日本福利一区二区精品| 国产XX00| 人妻第三页| 久久精品国产亚洲a| 91精品国产老熟女在线| 国产资源精品中文字幕| 国产精品久久精品第一页| 毛片无码高潮喷白浆视频| 乱码中字在线观看一二区| 亚洲av永久无码精品网站| 夜爽8888视频在线观看| 噜噜噜天天躁狠狠躁夜夜精品| 久久久久人妻精品一区三寸| 免费可以在线看a∨网站| 成在线人午夜剧场免费无码| 97久久精品午夜一区二区| 女人ZOZOZO人禽| 欧美天天干|